Literature DB >> 33563912

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.

Benjamin A Derman1, Andrew T Stefka1, Ken Jiang1, Amanda McIver1, Tadeusz Kubicki2, Jagoda K Jasielec1, Andrzej J Jakubowiak3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33563912      PMCID： PMC7873068          DOI： 10.1038/s41408-021-00418-2

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  12 in total

1.  Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.

Authors:  Luzalba Sanoja-Flores; Juan Flores-Montero; Noemi Puig; Teresa Contreras-Sanfeliciano; Roberia Pontes; Alba Corral-Mateos; Omar García-Sánchez; María Díez-Campelo; Roberto José Pessoa de Magalhães; Luis García-Martín; José María Alonso-Alonso; Aranzazú García-Mateo; Carlos Aguilar-Franco; Jorge Labrador; Abelardo Barez-García; Angelo Maiolino; Bruno Paiva; Jesús San Miguel; Elaine Sobral da Costa; Marcos González; María Victoria Mateos; Brian Durie; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

Review 2.  Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins.

Authors:  M Zajec; P Langerhorst; M M VanDuijn; J Gloerich; H Russcher; A J van Gool; T M Luider; I Joosten; Y B de Rijke; J F M Jacobs
Journal:  Clin Chem       Date:  2020-03-01       Impact factor: 8.327

3.  Laboratory persistence and clinical progression of small monoclonal abnormalities.

Authors:  David L Murray; Justin L Seningen; Angela Dispenzieri; Melissa R Snyder; Robert A Kyle; S Vincent Rajkumar; Jerry A Katzmann
Journal:  Am J Clin Pathol       Date:  2012-10       Impact factor: 2.493

4.  Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Authors:  Philippe Moreau; Michel Attal; Denis Caillot; Margaret Macro; Lionel Karlin; Laurent Garderet; Thierry Facon; Lotfi Benboubker; Martine Escoffre-Barbe; Anne-Marie Stoppa; Kamel Laribi; Cyrille Hulin; Aurore Perrot; Gerald Marit; Jean-Richard Eveillard; Florence Caillon; Caroline Bodet-Milin; Brigitte Pegourie; Veronique Dorvaux; Carine Chaleteix; Kenneth Anderson; Paul Richardson; Nikhil C Munshi; Herve Avet-Loiseau; Aurelie Gaultier; Jean-Michel Nguyen; Benoit Dupas; Eric Frampas; Françoise Kraeber-Bodere
Journal:  J Clin Oncol       Date:  2017-07-07       Impact factor: 44.544

5.  Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

Authors:  Jagoda K Jasielec; Tadeusz Kubicki; Noopur Raje; Ravi Vij; Donna Reece; Jesus Berdeja; Benjamin A Derman; Cara A Rosenbaum; Paul Richardson; Sandeep Gurbuxani; Sarah Major; Brittany Wolfe; Andrew T Stefka; Leonor Stephens; Kathryn M Tinari; Tyler Hycner; Alexandra E Rojek; Dominik Dytfeld; Kent A Griffith; Todd M Zimmerman; Andrzej J Jakubowiak
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

6.  Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.

Authors:  David R Barnidge; Surendra Dasari; Chad M Botz; Danelle H Murray; Melissa R Snyder; Jerry A Katzmann; Angela Dispenzieri; David L Murray
Journal:  J Proteome Res       Date:  2014-02-11       Impact factor: 4.466

7.  Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.

Authors:  John R Mills; Mindy C Kohlhagen; Surendra Dasari; Patrick M Vanderboom; Robert A Kyle; Jerry A Katzmann; Maria A V Willrich; David R Barnidge; Angela Dispenzieri; David L Murray
Journal:  Clin Chem       Date:  2016-08-18       Impact factor: 8.327

8.  Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.

Authors:  Ravi Vij; Amitabha Mazumder; Mark Klinger; Denise O'Dea; Jacob Paasch; Thomas Martin; Li Weng; Jeesun Park; Mark Fiala; Malek Faham; Jeffrey Wolf
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-10-02

Review 9.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

10.  Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Authors:  Aurore Perrot; Valerie Lauwers-Cances; Jill Corre; Nelly Robillard; Cyrille Hulin; Marie-Lorraine Chretien; Thomas Dejoie; Sabrina Maheo; Anne-Marie Stoppa; Brigitte Pegourie; Lionel Karlin; Laurent Garderet; Bertrand Arnulf; Chantal Doyen; Nathalie Meuleman; Bruno Royer; Jean-Richard Eveillard; Lotfi Benboubker; Mamoun Dib; Olivier Decaux; Arnaud Jaccard; Karim Belhadj; Sabine Brechignac; Brigitte Kolb; Cecile Fohrer; Mohamad Mohty; Margaret Macro; Paul G Richardson; Victoria Carlton; Martin Moorhead; Tom Willis; Malek Faham; Kenneth C Anderson; Jean-Luc Harousseau; Xavier Leleu; Thierry Facon; Philippe Moreau; Michel Attal; Hervé Avet-Loiseau; Nikhil Munshi
Journal:  Blood       Date:  2018-09-24       Impact factor: 25.476
View more
  7 in total

Review 1.  Bringing mass spectrometry into the care of patients with multiple myeloma.

Authors:  David L Murray
Journal:  Int J Hematol       Date:  2022-04-26       Impact factor: 2.490

2.  Minimal residual disease in multiple myeloma: why, when, where.

Authors:  Andrew J Yee; Noopur Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Authors:  Benjamin A Derman; Ankit Kansagra; Jeffrey Zonder; Andrew T Stefka; David L Grinblatt; Larry D Anderson; Sandeep Gurbuxani; Sunil Narula; Shayan Rayani; Ajay Major; Andrew Kin; Ken Jiang; Theodore Karrison; Jagoda Jasielec; Andrzej J Jakubowiak
Journal:  JAMA Oncol       Date:  2022-09-01       Impact factor: 33.006

4.  Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.

Authors:  Habib El-Khoury; David J Lee; Jean-Baptiste Alberge; Robert Redd; Christian J Cea-Curry; Jacqueline Perry; Hadley Barr; Ciara Murphy; Dhananjay Sakrikar; David Barnidge; Mark Bustoros; Houry Leblebjian; Anna Cowan; Maya I Davis; Julia Amstutz; Cody J Boehner; Elizabeth D Lightbody; Romanos Sklavenitis-Pistofidis; Mark C Perkins; Stephen Harding; Clifton C Mo; Prashant Kapoor; Joseph Mikhael; Ivan M Borrello; Rafael Fonseca; Scott T Weiss; Elizabeth Karlson; Lorenzo Trippa; Timothy R Rebbeck; Gad Getz; Catherine R Marinac; Irene M Ghobrial
Journal:  Lancet Haematol       Date:  2022-03-25       Impact factor: 30.153

5.  Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).

Authors:  Angela Dispenzieri; Amrita Krishnan; Bonnie Arendt; Beth Blackwell; Paul K Wallace; Surendra Dasari; Dan T Vogl; Yvonne Efebera; Mingwei Fei; Nancy Geller; Sergio Giralt; Theresa Hahn; Alan Howard; Mindy Kohlhagen; Heather Landau; Parameswaran Hari; Marcelo C Pasquini; Muzaffar H Qazilbash; Philip McCarthy; Nina Shah; David H Vesole; Edward Stadtmauer; David Murray
Journal:  Blood Cancer J       Date:  2022-02-10       Impact factor: 11.037

Review 6.  Liquid biopsies to occult brain metastasis.

Authors:  Asad Ur Rehman; Parvez Khan; Shailendra Kumar Maurya; Jawed A Siddiqui; Juan A Santamaria-Barria; Surinder K Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2022-05-10       Impact factor: 41.444

7.  Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Authors:  Noemí Puig; María-Teresa Contreras; Cristina Agulló; Joaquín Martínez-López; Albert Oriol; María-Jesús Blanchard; Rafael Ríos; Jesús Martín; María-Belén Iñigo; Anna Sureda; Miguel-Teodoro Hernández; Javier de la Rubia; Verónica González-Calle; Isabel Krsnik; Valentín Cabañas; Luis Palomera; José-María Moraleda; Joan Bargay; María-Teresa Cedena; Bruno Paiva; Laura Rosiñol; Joan Bladé; Jesús San Miguel; Juan-José Lahuerta; María-Victoria Mateos
Journal:  Blood Adv       Date:  2022-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.